{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:46:48Z","timestamp":1790729208550,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jtos.2020.05.008","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T12:20:39Z","timestamp":1589804439000},"page":"151-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Ocular surface disease associated with dupilumab treatment for atopic diseases"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4131-2532","authenticated-orcid":false,"given":"Canan Asli","family":"Utine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4318-7966","authenticated-orcid":false,"given":"Gavin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Asbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Pflugfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esen","family":"Akpek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2020.05.008_bib1","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: a review of its use in the treatment of atopic dermatitis","volume":"78","author":"Gooderham","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jtos.2020.05.008_bib2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtos.2020.05.008_bib3","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtos.2020.05.008_bib4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtos.2020.05.008_bib5","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4049\/jimmunol.136.7.2348","article-title":"Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins","volume":"136","author":"Mosmann","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.jtos.2020.05.008_bib6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1749-6632.1992.tb39751.x","article-title":"T lymphocyte subsets, cytokines, and effector functions","volume":"664","author":"Mosmann","year":"1992","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jtos.2020.05.008_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.iy.07.040189.001045","article-title":"TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties","volume":"7","author":"Mosmann","year":"1989","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jtos.2020.05.008_bib8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0167-5699(96)80606-2","article-title":"The expanding universe of T-cell subsets: Th1, Th2 and more","volume":"17","author":"Mosmann","year":"1996","journal-title":"Immunol Today"},{"key":"10.1016\/j.jtos.2020.05.008_bib9","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2008-05-078154","article-title":"CD4 T cells: fates, functions, and faults","volume":"112","author":"Zhu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtos.2020.05.008_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-065X.2010.00951.x","article-title":"Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors","volume":"238","author":"Zhu","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jtos.2020.05.008_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-3-319-64804-0_3","article-title":"Atopic dermatitis: pathophysiology","volume":"1027","author":"David Boothe","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jtos.2020.05.008_bib12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature07204","article-title":"The development of allergic inflammation","volume":"454","author":"Galli","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jtos.2020.05.008_bib13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.exer.2013.08.013","article-title":"T helper cytokines in dry eye disease","volume":"117","author":"Pflugfelder","year":"2013","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jtos.2020.05.008_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1350-9462(02)00006-X","article-title":"Vernal keratoconjunctivitis: pathogenesis and treatment","volume":"21","author":"Leonardi","year":"2002","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jtos.2020.05.008_bib15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.preteyeres.2005.09.002","article-title":"Role of structural cells of the cornea and conjunctiva in the pathogenesis of vernal keratoconjunctivitis","volume":"25","author":"Kumagai","year":"2006","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jtos.2020.05.008_bib16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1365-2222.2006.02499.x","article-title":"Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures","volume":"36","author":"Leonardi","year":"2006","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jtos.2020.05.008_bib17","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1056\/NEJM199712113372403","article-title":"The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor","volume":"337","author":"Hershey","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtos.2020.05.008_bib18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1167\/iovs.07-1401","article-title":"Association of combined IL-13\/IL-4R signaling pathway gene polymorphism with Stevens-Johnson syndrome accompanied by ocular surface complications","volume":"49","author":"Ueta","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Suppl 1","key":"10.1016\/j.jtos.2020.05.008_bib19","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1097\/ICO.0b013e31817f2a7f","article-title":"Innate immunity of the ocular surface and ocular surface inflammatory disorders","volume":"27","author":"Ueta","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2020.05.008_bib20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/ICL.0b013e3181ee8971","article-title":"Ocular surface inflammation mediated by innate immunity","volume":"36","author":"Ueta","year":"2010","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.jtos.2020.05.008_bib21","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1167\/iovs.14-15496","article-title":"IL-13 stimulates proliferation and expression of mucin and immunomodulatory genes in cultured conjunctival goblet cells","volume":"56","author":"Tukler Henriksson","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2020.05.008_bib22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/mi.2010.82","article-title":"Homeostatic control of conjunctival mucosal goblet cells by NKT-derived IL-13","volume":"4","author":"De Paiva","year":"2011","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jtos.2020.05.008_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000236842","article-title":"Immunoregulatory properties of IL-13: its potential role in atopic disease","volume":"106","author":"de Vries","year":"1995","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jtos.2020.05.008_bib24","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/intimm\/7.9.1405","article-title":"Differential regulation of IL-13 and IL-4 production by human CD8+ and CD4+ Th0, Th1 and Th2 T cell clones and EBV-transformed B cells","volume":"7","author":"de Waal Malefyt","year":"1995","journal-title":"Int Immunol"},{"key":"10.1016\/j.jtos.2020.05.008_bib25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2249.1995.tb02291.x","article-title":"IL-13 results in differential regulation of the complement proteins C3 and factor B in tumour necrosis factor (TNF) \u2013stimulated fibroblasts","volume":"101","author":"Katz","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jtos.2020.05.008_bib26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00004397-198802840-00016","article-title":"The complement system in ocular allergy","volume":"28","author":"Mondino","year":"1988","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.jtos.2020.05.008_bib27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0091-6749(85)90729-8","article-title":"Complement proteins and C3 anaphylotoxin in the tears of patients with conjunctivitis","volume":"76","author":"Ballow","year":"1985","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2020.05.008_bib28","first-page":"467","article-title":"The pathology of vernal conjunctivitis","volume":"91","author":"Morgan","year":"1971","journal-title":"Trans Ophthalmol Soc U K"},{"key":"10.1016\/j.jtos.2020.05.008_bib29","first-page":"858","article-title":"Basophils in vernal conjunctivitis in humans: an electron microscope study","volume":"16","author":"Collin","year":"1977","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2020.05.008_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/09273949409057069","article-title":"Atopic keratoconjunctivitis","volume":"2","author":"Akova","year":"1994","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jtos.2020.05.008_bib31","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/bjo.79.5.482","article-title":"Collagen types I and III in giant papillae of vernal conjunctivitis","volume":"79","author":"Leonardi","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2020.05.008_bib32","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1046\/j.1365-2222.1999.00585.x","article-title":"Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease","volume":"29","author":"Calder","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jtos.2020.05.008_bib33","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.4049\/jimmunol.146.4.1169","article-title":"Accumulation of TH2-like helper T cells in the conjunctiva of patients with vernal conjunctivitis","volume":"146","author":"Maggi","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.jtos.2020.05.008_bib34","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0091-6749(97)70279-3","article-title":"T cell cytokines in chronic allergic eye disease","volume":"100","author":"Metz","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2020.05.008_bib35","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1080\/09273948.2018.1511811","article-title":"Immunopathological features of severe chronic atopic keratoconjunctivitis and effects of topical cyclosporine treatment","volume":"27","author":"Utine","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jtos.2020.05.008_bib36","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0091-6749(96)70103-3","article-title":"Phenotypic characterization of T cells infiltrating the conjunctiva in chronic allergic eye disease","volume":"98","author":"Metz","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2020.05.008_bib37","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1365-2222.2004.1950.x","article-title":"No apparent association between periocular and ocular microcolonization and the degree of inflammation in patients with atopic keratoconjunctivitis","volume":"34","author":"Nivenius","year":"2004","journal-title":"Clin Exp Allergy"},{"issue":"Suppl 2","key":"10.1016\/j.jtos.2020.05.008_bib38","first-page":"S51","article-title":"Potential biomarkers for allergic conjunctival diseases","volume":"46","author":"Roy","year":"2020","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.jtos.2020.05.008_bib39","doi-asserted-by":"crossref","first-page":"e1735","DOI":"10.1542\/peds.2014-2812","article-title":"Atopic dermatitis: skin-directed management","volume":"134","author":"Tollefson","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.jtos.2020.05.008_bib40","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","article-title":"Ocular surface diseases induced by dupilumab in severe atopic dermatitis","volume":"8","author":"Maudinet","year":"2019","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"10.1016\/j.jtos.2020.05.008_bib41","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jaip.2018.10.009","article-title":"Atopic dermatitis is associated with increased prevalence of multiple ocular comorbidities","volume":"7","author":"Govind","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jtos.2020.05.008_bib42","doi-asserted-by":"crossref","first-page":"E978","DOI":"10.3390\/ijms18050978","article-title":"Goblet cells contribute to ocular surface immune tolerance-implications for dry eye disease","volume":"18","author":"Barbosa","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtos.2020.05.008_bib43","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/intimm\/dxy045","article-title":"Goblet cell produced retinoic acid suppresses CD86 expression and IL-12 production in bone marrow derived cells","volume":"30","author":"Xiao","year":"2018","journal-title":"Int Immunol"},{"key":"10.1016\/j.jtos.2020.05.008_bib44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00004397-199803810-00013","article-title":"Vitamin A deficiency and its effects on the eye","volume":"38","author":"Harris","year":"1998","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.jtos.2020.05.008_bib45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.survophthal.2014.10.001","article-title":"Retinoic acid and the ocular surface","volume":"60","author":"Samarawickrama","year":"2015","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jtos.2020.05.008_bib46","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jtos.2019.12.006","article-title":"Immune - goblet cell interaction in the conjunctiva","volume":"18","author":"Alam","year":"2020","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2020.05.008_bib47","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s00347-017-0483-1","article-title":"[Pathophysiology of atopic blepharokeratoconjunctivitis]","volume":"114","author":"Lapp","year":"2017","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.jtos.2020.05.008_bib48","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2012.04.001","article-title":"In vivo confocal microscopy evaluation of meibomian gland dysfunction in atopic-keratoconjunctivitis patients","volume":"119","author":"Ibrahim","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2020.05.008_bib49","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/ICO.0b013e31822481c2","article-title":"Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis","volume":"31","author":"Tzu","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2020.05.008_bib50","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/ACI.0b013e328364d86a","article-title":"Immunomodulators for conjunctivitis","volume":"13","author":"Pacharn","year":"2013","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2020.05.008_bib51","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.anai.2019.01.004","article-title":"The efficacy of 0.1% tacrolimus ophthalmic suspension in the treatment of severe atopic keratoconjunctivitis","volume":"122","author":"Yazu","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jtos.2020.05.008_bib52","first-page":"392","article-title":"The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis","volume":"40","author":"Hingorani","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2020.05.008_bib53","article-title":"Innovation in atopic dermatitis: from pathogenesis to treatment","author":"Munera-Campos","year":"2020","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.jtos.2020.05.008_bib54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2020.05.008_bib55","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/JAA.S211032","article-title":"Therapeutic potential of lebrikizumab in the treatment of atopic dermatitis","volume":"13","author":"Loh","year":"2020","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jtos.2020.05.008_bib56","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jtos.2020.05.008_bib57","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2020.05.008_bib58","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jtos.2020.05.008_bib59","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtos.2020.05.008_bib60","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtos.2020.05.008_bib61","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtos.2020.05.008_bib62","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtos.2020.05.008_bib63","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtos.2020.05.008_bib64","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtos.2020.05.008_bib65","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtos.2020.05.008_bib66","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jtos.2020.05.008_bib68","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/09546634.2017.1373736","article-title":"New and emerging targeted systemic therapies: a new era for atopic dermatitis","volume":"29","author":"Lee","year":"2018","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jtos.2020.05.008_bib69","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2340\/00015555-3121","article-title":"Eye complications during dupilumab treatment for severe atopic dermatitis","volume":"99","author":"Ivert","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jtos.2020.05.008_bib70","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti\u2013IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jtos.2020.05.008_bib71","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jaip.2018.01.034","article-title":"Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab \u2013 clinical characteristics and treatment","volume":"6","author":"Wollenberg","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jtos.2020.05.008_bib72","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk factors for dupilumab associated conjunctivitis in patients with atopic dermatitis","volume":"154","author":"Treister","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jtos.2020.05.008_bib73","doi-asserted-by":"crossref","DOI":"10.1097\/ICO.0000000000002262","article-title":"Dupilumab-associated conjunctivitis in patients with atopic dermatitis","author":"Liberman","year":"2020","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2020.05.008_bib74","first-page":"1","article-title":"Punctal stenosis associated with dupilumab therapy for atopic dermatitis","author":"Lee","year":"2020","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jtos.2020.05.008_bib75","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/09273948.2018.1533567","article-title":"Dupilumab-induced follicular conjunctivitis","volume":"27","author":"Shen","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jtos.2020.05.008_bib76","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jaip.2018.10.055","article-title":"Letter regarding \u2018Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab \u2013 clinical characteristics and treatment\u2019","volume":"7","author":"Rial","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jtos.2020.05.008_bib77","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jaip.2018.10.054","article-title":"Reply","volume":"7","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jtos.2020.05.008_bib78","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ijwd.2019.10.001","article-title":"Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD)","volume":"5","author":"Raffi","year":"2019","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.jtos.2020.05.008_bib79","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01676830.2018.1553190","article-title":"Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis","volume":"38","author":"Yamane","year":"2019","journal-title":"Orbit"},{"key":"10.1016\/j.jtos.2020.05.008_bib80","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jdcr.2018.10.016","article-title":"Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): a novel case report","volume":"5","author":"Zirwas","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jtos.2020.05.008_bib81","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtos.2020.05.008_bib82","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMc1700366","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"376","author":"Mennini","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtos.2020.05.008_bib83","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1167\/tvst.9.3.29","article-title":"Dupilumab-associated mucin deficiency (DAMD)","volume":"9","author":"Barnett","year":"2020","journal-title":"Trans Vis Sci Technol"},{"key":"10.1016\/j.jtos.2020.05.008_bib84","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.oftal.2019.04.013","article-title":"Cyclosporine 0.1% (Ikervis\u00ae) treatment in steroid-dependent dupilumab-associated conjunctivitis","volume":"94","author":"Roca-Gin\u00e9s","year":"2019","journal-title":"Arch Soc Esp Oftalmol"},{"key":"10.1016\/j.jtos.2020.05.008_bib85","doi-asserted-by":"crossref","first-page":"100550","DOI":"10.1016\/j.ajoc.2019.100550","article-title":"Dupilumab-associated blepharoconjunctivitis","volume":"16","author":"Paulose","year":"2019","journal-title":"Am J Ophthalmol Case Rep"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012420300860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012420300860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:43:59Z","timestamp":1761540239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012420300860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":84,"alternative-id":["S1542012420300860"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2020.05.008","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular surface disease associated with dupilumab treatment for atopic diseases","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2020.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}